SCHEMBL721977

SCHEMBL721977

COc1cc(N)cc(-c2cc3nccc(-c4cnn(C)c4)c3o2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.38
MAP3K7 O43318 2/20 0.38
TAB1 Q15750 2/20 0.38
AURKB Q96GD4 2/20 0.38
FGFR3 P22607 11/20 0.38
FGFR2 P21802 10/20 0.38
FGFR1 P11362 9/20 0.38
KCNH2 Q12809 1/20 0.37
GRM4 Q14833 1/20 0.37
FGFR4 P22455 6/20 0.37
FLT3 P36888 3/20 0.36
MET P08581 2/20 0.36
AURKA O14965 1/20 0.36
INCENP Q9NQS7 1/20 0.36
TPX2 Q9ULW0 1/20 0.36
LRRK2 Q5S007 1/20 0.35
MTOR P42345 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
TTK P33981 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL725506 0.86 KCNH2 (0.43) KDRAURKBFGFR3FGFR2FGFR1
SCHEMBL10268949 0.83 AURKB (0.46) KDRMAP3K7TAB1AURKBFGFR3
SCHEMBL721974 0.83 MAP3K7 (0.44) KDRMAP3K7TAB1AURKBMET
SCHEMBL721487 0.83 ADORA2A (0.45) KDR
SCHEMBL722228 0.82 PDE4C (0.43) AURKBMETAURKAINCENPTPX2
SCHEMBL724888 0.81 ACVR2A (0.48) KDRMAP3K7TAB1AURKBAURKA
SCHEMBL722397 0.81 AURKB (0.44) KDRMAP3K7TAB1AURKBMET
SCHEMBL721816 0.80 LRRK2 (0.45) KCNH2GRM4FLT3METLRRK2
SCHEMBL10267309 0.80 MKNK1 (0.43) KDRAURKBFGFR3FGFR2FGFR1
SCHEMBL722106 0.80 MTOR (0.47) KDRMAP3K7TAB1AURKBMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB KDR 263/4885MAP3K7 621/4885TAB1 507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.